Now also in Germany: BIOIBERICA International Specialist in the Field of Osteoarthritis
|| Print ||
|Thursday, 27 October 2011 15:15 (UTC + 2)|
Munich, October 27, 2011 / B3C newswire / - Bioiberica, one of the world's leading companies in the field of joint health, is now active in Germany: starting immediately, trading by Bioiberica GmbH is being controlled from the new head office in Munich. The company has been researching, developing, producing and marketing pharmaceuticals and dietary substances of the highest quality for more than 35 years. Bioiberica was founded in 1975 in Barcelona, Spain, and is now present in more than 70 countries world-wide.
One of Bioiberica's main focuses is on the field of osteoarthritis. "Doctors and patients all over the world put their trust in our broad product portfolio of chondroprotectives, such as chondroitin sulphate, glucosamine and hyaluronic acid. We are very pleased that we will soon be making our first contribution to the dietary care of patients with osteoarthritis with our first product in Germany" explained Axel Schmidt, pharmacist and Division Director of Bioiberica GmbH. The company has not only made a name for itself wtih chondroprotectives, but also with the research and development of heparins.
The efficacy and safety of the Bioiberica products have been proved in comprehensive clinical trials as well as in numerous international articles and publications.
Scientific expertise – holistic approach to osteoarthritis
Research & development spans from personalised diagnostics (including biomarkers) to prevention and medication-based treatment right up, to dietary care for patients with osteoarthritis and other joint problems.
Research, production and innovation with experience
Part of the world-wide scientific network
Health solutions and committment to protecting the environment
Incidentally, Bioiberica is one of the first pharmaceutical companies to have integrated the environmental guidelines as a central module in its corporate policy and to adapt its production processes to the ecological balance. For instance, the company invests about 2.5% of its sales in environmental protection alone.
Background information on osteoarthritis
Osteoarthritis describes the condition following the destruction of the catrilage layer in a joint and the associated bony changes. The pathophysiology has still not been completely explained. However, three different stages of development can usually be recognised:
Possible risk factors for osteoarthritis include hereditary predisposition, congenital deformities of the joints, injuries, long-term overuse and metabolic diseases.
While osteoarthritis has usually been considered the result of wear and tear to date – a sort of unavoidable fate – new findings in pathophysiology have shown real possibilities for effective therapeutic intervention.